Human Allogeneic Cardiosphere-Derived Cells
Muscular Dystrophy
Explore 5 assets in Muscular Dystrophy →Floatz Rating
B57/100
Confidence
Indicative
Sponsor
Capricor Inc.
Modality
Cell therapy
Development Phase
Phase 2
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
42Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT03406780CT.gov A Study of CAP-1002 in Ambulatory and Non-Ambulatory Patients With Duchenne Muscular Dystrophy | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Muscular Dystrophy
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Human Allogeneic Cardiosphere-Derived Cells (this asset) | Capricor Inc. | P2 | B · 57 |
| gsk2402968 | GlaxoSmithKline | P3 | BB |
| Ataluren | PTC Therapeutics | P3 | B |
| Zeleciment Rostudirsen | Dyne Therapeutics | P3 | B |
| Deramiocel | Capricor Inc. | P3 | B |
| Aoc 1044 | Avidity Biosciences, Inc. | P3 | B |
| Tadalafil | University of Florida | P2 | B |
| Enalapril | InCor Heart Institute | P3 | B |
| Sat-3247 | Satellos Bioscience, Inc. | P2 | CCC |
+2 more in the Muscular Dystrophy cohort
Other indications for Human Allogeneic Cardiosphere-Derived Cells
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Duchenne Muscular Dystrophy | — | P2 | B · 63 |
| X-Linked Disease | — | P2 | B · 57 |
| Nervous System Disorder | — | P2 | B · 57 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Human Allogeneic Cardiosphere-Derived Cells in Muscular Dystrophy. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/human-allogeneic-cardiosphere-derived-cells-muscular-dystrophy
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →